Amsterdam, The Netherlands, March 20, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017. Jan… Continue reading Kiadis Pharma appoints Jan Feijen as Chief Operations Officer
Blog posts
Kiadis Pharma issues clinical and regulatory progress update on ATIR101™ and ATIR201™
~ Pivotal Phase III trial with ATIR101™ initiated ~ ~ MAA submission to EMA for ATIR101™ progressing well ~ Amsterdam, The Netherlands, February 6, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood… Continue reading Kiadis Pharma issues clinical and regulatory progress update on ATIR101™ and ATIR201™
Kiadis Pharma provides update on second dose trial (CR-AIR-008) with ATIR101™
~ Trial continues according to protocol with one dose ~ Amsterdam, The Netherlands, December 21, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces an update on the second dose… Continue reading Kiadis Pharma provides update on second dose trial (CR-AIR-008) with ATIR101™
Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia
Amsterdam, The Netherlands, December 15, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approval from the national authority in the United Kingdom (the MHRA,… Continue reading Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia
Planned Management Team Changes
Amsterdam, The Netherlands, December 8, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that Arthur Lahr will join Kiadis Pharma on January 1, 2017 as Chief Operating Officer (COO)… Continue reading Planned Management Team Changes
